National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Cost-effectiveness of oral oxycodone/naloxone prolonged release tablet (Targin®) for severe pain, which can be adequately managed only with opioid analgesics.

Pharmacoeconomic Evaluation

Commenced Completed Outcome
05/05/2010 12/07/2010 Reimbursement not recommended
19/10/2010 Reimbursement recommended following price revision

We do not recommend reimbursement of oxycodone/naloxone (Targin®) under the Community Drugs Schemes at the proposed price.

Following a price revision oxycodone/naloxone (Targin®) is now reimbursed under the Community Drugs Schemes.

Oxycodone/naloxone (Targin®) summary